NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT technology, announced that the Canadian Patent Office has issued a Notice of Allowance for NexMed’s patent application entitled, 'Crystalline Salts of Dodecyl 2-(N,N-Dimethylamino)-Propionate.'
The said patent, when issued, will provide Canadian patent protection to May 2020, and is one in a series of patents and pending applications that NexMed owns on the NexACT technology and NexACT-based products under development. A Notice of Allowance confirms that the patent application has been examined and is allowed for issuance as a patent and that the prosecution on the merits is closed.
Dr Bassam Damaj, president and chief executive officer of NexMed, stated, “The company has a strong intellectual property position. In addition to the allowance in Canada, we have corresponding coverage and protection for our NexACT technology in the US and other major markets. As we pursue our growth goals, we are aggressively seeking to expand the patent coverage for NexACT and to protect its potential for delivering new classes of drugs and/or via new routes of administration such as oral or subcutaneous delivery”.
NexMed is the largest specialty CRO based in San Diego, California and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models.